Document is current

Article History

Received: 19 May 2019

First Online: 17 December 2019

Disclosures

: This study was presented in plenary podium format at the 71st Annual Meeting of the Society of Surgical Oncology, March 21–24, 2018, Chicago, IL. Drs. Hollmann, Coit, and Brady have no disclosures. Dr. Bello has worked as a consultant for survivornet. Dr. Panageas has stock ownership in Johnson and Johnson, Pfizer, Viking Therapeutics, and Catalyst Biotech. Dr. Shoushtari serves on the advisory board for Bristol-Myers Squibb (BMS), Castle Biosciences, and Immunocore. He receives institutional research support from BMS, Immunocore, AstraZeneca, and Xcovery. Dr. Chapman receives consulting, advisory, or speaking compensation from Immunocore, Merck, Cell Medica, Takeda Millenium, and AstraZeneca. He holds stock in Rgenix. He receives research support from Pfizer. Dr. Postow has worked as a consultant for: BMS, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics, Aduro. He has received honoraria from: BMS and Merck. He receives institutional research support from: RGenix, Infinity, BMS, Merck, Array BioPharma, Novartis, and AstraZeneca. Dr. Callahan reports grants from and employment of a family member by BMS; personal fees for advisory/consulting role from AstraZeneca/MedImmune, Incyte, Moderna and Merck. Dr. Wolchok is a consultant for: Adaptive Biotech, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, Astellas, Bayer, Beigene, BMS, Celgene, Chugai, Elucida, Eli Lilly, F Star, Genentech, Imvaq, Janssen, Kleo Pharma, Linneaus, MedImmune, Merck, Neon Therapeutics, Ono Pharmaceuticals, Polaris Pharma, Polynoma, Psioxus, Puretech, Recepta, Sellas Life Sciences, Serametrix, Surface Oncology, Syndax. He receives research support from: BMS, Medimmune, Genentech. He has equity in: Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, Beigene, Trieza, Serametrix, Linneaus. He receives honorarium from: Esanex. Dr. Ariyan served on an advisory board for BMS.